Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza chłoniaka T-komórkowego (mycosis fungoides, Zespół Sézary'ego, pierwotny chłoniak skóry, chłoniak obwodowy lub angioimmunoblastyczny)
- •Choroba oporów lub wznowiona po co najmniej jednym wcześniejszym leczeniu
- •Możliwość zmierzenia zmian choroby za pomocą dostępnych badań
- •Chłoniaki skórne w stadium IB-IV lub chłoniaki węzłowe w stadium II-IV
- •Co najmniej 4 tygodnie od ostatniego leczenia systemowego lub radioterapii (6 tygodni dla wybranych chemioterapii)
- •Wyleczenie się z powikłań poprzedniego leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Mayo Clinic Arizona
Scottsdale, United States
City of Hope Medical Foundation
Duarte, United States
University of Southern California
Los Angeles, United States
University of Colorado Anschutz Medical Campus
Aurora, United States
Northwestern University, Robert H. Lurie Comprehensive Cancer Center
Chicago, United States
University of Michigan
Ann Arbor, United States
Barbara Ann Karmanos Cancer Institute Wayne State University
Detroit, United States
Columbia University
New York, United States
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Trial contact
Louis M Scarmoutzos, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.